#	Pagina
attuale pagina	/open-h2020/projects/220854/index.html

Opendata, web and dolomites

ViroPedTher SIGNED

Oncolytic viruses for the treatment of pediatric brain tumors: An integrated clinical and lab approach

Total Cost €

EC-Contrib. €

Partnership

Views

ViroPedTher project word cloud

Explore the words cloud of the ViroPedTher project. It provides you a very rough idea of what is the project "ViroPedTher" about.

ultimately instigated immunosuppression team previously 2401 replication lethal scenario 24 virus inherent elicit experimental intrinsic trial infiltrating microenvironment tumors understand improvement prognosis ed risk capacity context delayed clinical brain subset initial lymphocytes revealed dipgs rgd adenovirus diffuse therapy oncolytic translated competence complete toxicities hypothesized recruit profound delta ligands models dipg tumor diagnosed 2017 newly lab immune treatment dnx regression adenoviruses trials oncolysis first patients propelled viral therapeutic followed ing competent oncology injection pediatric inflammatory worked innovative activate combinatorial overreaching vast anti majority pontine enhancement vertical integrate leverage gliomas preliminary life turn quality opened intratumoral

Project "ViroPedTher" data sheet

The following table provides information about the project.

Coordinator	UNIVERSIDAD DE NAVARRA Organization address address: CAMPUS UNIVERSITARIO EDIFICIO CENTRAL city: PAMPLONA postcode: 31080 website: www.unav.es contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Spain [ES]
Total cost	2˙000˙000 €
EC max contribution	2˙000˙000 € (100%)
Programme	1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
Code Call	ERC-2018-COG
Funding Scheme	ERC-COG
Starting year	2019
Duration (year-month-day)	from 2019-03-01 to 2024-02-29

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	UNIVERSIDAD DE NAVARRA UNIVERSIDAD DE NAVARRA Organization address address: CAMPUS UNIVERSITARIO EDIFICIO CENTRAL city: PAMPLONA postcode: 31080 website: www.unav.es contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (PAMPLONA)	coordinator	2˙000˙000.00

Map

Project objective

The overreaching goal of my lab is to improve the prognosis of patients with high-risk pediatric brain tumors. To this end, I propose to integrate clinical and lab-based research to develop tumor-targeted oncolytic adenoviruses with the capacity to elicit a therapeutic immune response in those tumors. Our research will use novel and relevant models to accomplish the experimental aims. We have previously worked with Delta-24-RGD (DNX-2401) a replication-competent adenovirus that has been translated to the clinical scenario. In 2017, the first clinical trial phase I with DNX-2401 for newly diagnosed Diffuse Intrinsic Pontine Gliomas (DIPG; a lethal pediatric brain tumor) opened propelled by my team. Preliminary results from the first trials revealed that the intratumoral injection of the virus instigated an initial phase of oncolysis followed by a delayed inflammatory response that ultimately resulted in complete regression in a subset of the patients without associated toxicities. I hypothesized that enhancement of the immune component of the DNX-2401-based therapy will result in the complete regression of the vast majority of pediatric brain tumors. In our specific approach, we propose to understand the immune microenvironment of DIPGs and the response to viral therapy in the context of the trial. Moreover, that knowledge will leverage the design of Delta-24-based adenoviruses to recruit lymphocytes to the tumor with the competence of different type of ligands to activate the tumor infiltrating lymphocytes. I expect that this combinatorial innovative treatment will efficiently challenge the profound and inherent tumor immunosuppression and, in turn, will elicit a robust anti-tumor immune response resulting in the significant improvement of the prognosis and quality of life of patients with pediatric brain tumors. This project has the potential to produce a vertical advance in the field of pediatric oncology.

Publications

List of publications.
year	authors and title	journal	last update
2019	Naiara MartÃnez-VÃ©lez, Marc Garcia-Moure, Miguel Marigil, Marisol GonzÃ¡lez-Huarriz, Montse Puigdelloses, Jaime Gallego PÃ©rez-Larraya, Marta ZalacaÃn, LucÃa MarrodÃ¡n, Maider Varela-Guruceaga, Virginia Laspidea, Jose Javier Aristu, Luis Isaac Ramos, Sonia Tejada-SolÃs, Ricardo DÃez-Valle, Chris Jones, Alan Mackay, Jose A. MartÃnez-Climent, Maria Jose GarcÃa-Barchino, Eric Raabe, Michelle The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models published pages: , ISSN: 2041-1723, DOI: 10.1038/s41467-019-10043-0	Nature Communications 10/1	2020-02-05
2019	Ignacio IÃ±igo-Marco, Marta M. Alonso Destress and do not suppress: targeting adrenergic signaling in tumor immunosuppression published pages: 5086-5088, ISSN: 0021-9738, DOI: 10.1172/jci133115	Journal of Clinical Investigation 129/12	2020-02-05
2019	Donatas StakiÅ¡aitis, Milda JukneviÄienÄ—, Eligija DamanskienÄ—, Angelija ValanÄiÅ«tÄ—, Ingrida BalnytÄ—, Marta Maria Alonso The Importance of Gender-Related Anticancer Research on Mitochondrial Regulator Sodium Dichloroacetate in Preclinical Studies In Vivo published pages: 1210, ISSN: 2072-6694, DOI: 10.3390/cancers11081210	Cancers 11/8	2020-02-05
2019	Naiara Martinez-Velez, Miguel Marigil, Marc GarcÃa-Moure, Marisol Gonzalez-Huarriz, Jose Javier Aristu, Luis-Isaac Ramos-GarcÃa, Sonia Tejada, Ricardo DÃez-Valle, Ana PatiÃ±o-GarcÃa, Oren J. Becher, Candelaria Gomez-Manzano, Juan Fueyo, Marta M. Alonso Delta-24-RGD combined with radiotherapy exerts a potent antitumor effect in diffuse intrinsic pontine glioma and pediatric high grade glioma models published pages: , ISSN: 2051-5960, DOI: 10.1186/s40478-019-0714-6	Acta Neuropathologica Communications 7/1	2020-02-05
2019	Marc Garcia-Moure, Naiara Martinez-Velez, Marisol Gonzalez-Huarriz, LucÃa MarrodÃ¡n, Manel Cascallo, RamÃ³n Alemany, Ana PatiÃ±o-GarcÃa, Marta M. Alonso The oncolytic adenovirus VCN-01 promotes anti-tumor effect in primitive neuroectodermal tumor models published pages: , ISSN: 2045-2322, DOI: 10.1038/s41598-019-51014-1	Scientific Reports 9/1	2020-02-05

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "VIROPEDTHER" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "VIROPEDTHER" are provided by the European Opendata Portal: CORDIS opendata.